Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY: ABT )

129.89 -0.39 (-0.30%)
Official Closing Price Updated: 7:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
3 MedTech Stocks to Buy for Healthy Gains
With innovations in healthcare moving at a rapid clip, investors should consider these enticing MedTech stocks to buy. 
Via InvestorPlace
Market Whales and Their Recent Bets on ABT Options
Via Benzinga
Stocks Going Ex Dividend In July 2024
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors interested in the stock trading technique known as... 
Via Talk Markets
Hot Summer Dividends: 3 Sizzling Stocks to Buy for Reliable Income
Buying dividend stocks for income is a smart investment strategy to juice your portfolio's returns even in down markets. 
Via InvestorPlace
Top Analyst Reports For Abbott, BP & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
10 Stocks to Build a Dividend Portfolio That Will Pay You $1,000s per Year
The power of compounding can build huge amounts of passive income. 
Via The Motley Fool
Abbott Laboratories's Options: A Look at What the Big Money is Thinking
Via Benzinga
These Dividend Stocks Are an Investor's Best Friend
These two healthcare stocks are well-known for their top-tier dividend programs. 
Via The Motley Fool
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
These healthcare players offer you dividends and a strong earnings picture. 
Via The Motley Fool
2 Healthcare Stocks to Buy Hand Over Fist in June
They both have pretty impressive pasts, and their prospects look just as bright. 
Via The Motley Fool
2 Magnificent Dividend Growth Stocks to Buy Now
These two dividend growth stocks are potent capital appreciation vehicles. 
Via The Motley Fool
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
Class Action Against Abbott's Glucerna Products Proceeds in Federal Court
WuXi AppTec employees collaborated with China's PLA on altitude sickness drugs, raising national security concerns in the U.S. Congressional committee calls for restricting biotech ties amid ongoing... 
Via Benzinga
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
Looking At Abbott Laboratories's Recent Unusual Options Activity
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Berkshire Hathaway, Chipotle, More NYSE Stocks Hit With Trading Halts Triggered By Technical Issues
NYSE experiences trading halts Monday due to a technical issue. Stocks like Berkshire Hathaway and Chipotle are impacted. 
Via Benzinga
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Vertex might not present a clear and present danger to Abbott and DexCom but could present a clear future threat. 
Via The Motley Fool
The 3 Best MedTech Stocks to Buy Now: May 2024
Explore the best MedTech stocks to buy now that are driven by AI's potential to revolutionize healthcare efficiency. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for May 2024
Investors would be wise to pay attention to the analyst ratings on these leading healthcare stocks to buy, which are expected to rise. 
Via InvestorPlace
Reliable Rewards: 7 Dividend Stocks to Count On in Any Market
With uncertainty clouding the market, investors can sleep a little easier at night with these reliable dividend stocks. 
Via InvestorPlace
Blue-Chip Bonanza: 3 Stocks to Ride the Market’s Coattails to Riches
The bull market momentum is unstoppable and these blue-chip stocks have the earnings growth to drive upside. 
Via InvestorPlace
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Critical Insights From Abbott Laboratories Analyst Ratings: What You Need To Know
Via Benzinga
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
EQNX::TICKER_START (OTCPK:MUSLF),(CSE:MUSL),(NYSE:ABT),(NASDAQ:CELH),(NASDAQ:MNST),(NYSE:BRBR) EQNX::TICKER_END 
Via FinancialNewsMedia
Jim Cramer Calls This Healthcare Stock A 'Worthy Spec,' Recommends Avoiding Canada Goose
Cramer recommends staying away from Canada Goose, even though it reported better-than-expected Q4 earnings. 
Via Benzinga
3 S&P 500 Stocks That Have Proven Themselves Recession-Proof
Corrections are a part of investing and investors would be smart to have these three S&P 500 stocks to buy when the inevitable happens. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Global Sports Nutrition Market Projected to Reach $78 Billion as Muscle Repair & Growth Becoming Vitally Important
From FN Media Group LLC
Via GlobeNewswire
Best Foundational Stocks
Building the foundation of investors portfolio with the best US foundational stocks by sector. 
Via Talk Markets
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.